Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo's experimental CagriSema injection showed 25% weight loss in women in a late-stage analysis, improving on the results of its blockbuster GLP-1 obesity drug Wegovy. The new evidence suggests CagriSema could offer a more effective treatment option for obesity, potentially strengthening Novo's position in the competitive weight-loss market.